SecBot SecBot
PRESS-RELEASE ·Filed Mar 4, 2026

KROS

Keros Therapeutics, Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The sharp improvement in financials is non-recurring and tied to the Takeda license deal. Investors should focus on upcoming clinical milestones for rinvatercept in DMD and ALS as the next value drivers. The share repurchase significantly reduced cash, but runway remains sufficient into 2028.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.71
T+0 close · Mar 4, 2026 · via day close
Latest settled
−6.92%
T+60 · $10.90
Vs SPY
−18.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $11.71entry
  2. T+1 · 9mo ago −3.50%α −2.19% · $11.30
  3. T+5 · 8mo ago −6.15%α −3.91% · $10.99
  4. T+20 · 8mo ago +2.48%α +6.27% · $12.00
  5. T+60 · 6mo ago −6.92%α −18.22% · $10.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Keros Therapeutics reported a net income of $87.0 million for 2025, a significant improvement from a $187.4 million net loss in 2024, driven primarily by $205.4 million in license revenue from Takeda. The company is advancing rinvatercept into a Phase 2 trial for Duchenne muscular dystrophy in Q2 2026 and plans regulatory engagement for an ALS trial. Cash reserves decreased to $287.4 million from $559.9 million, but the company expects this to fund operations into early 2028.

Key Financial Metrics

Revenue
$244.1M
+6759.5% YoY
EPS
$2.34
Deal Value
$205.4M

Key Facts

  • Net income of $87.0 million in 2025 vs. $187.4 million net loss in 2024, driven by $205.4 million in license revenue from Takeda
  • R&D expenses declined to $129.6 million in 2025 from $173.6 million in 2024 due to transition of elritercept R&D to Takeda
  • Cash and cash equivalents dropped to $287.4 million as of Dec 31, 2025 from $559.9 million in 2024, primarily due to share repurchase and tender offer
  • Company expects cash runway into first half of 2028
  • Phase 2 trial for rinvatercept in DMD expected to start in Q2 2026; regulatory discussions for ALS trial planned in second half of 2026
  • Board changes: Charles Newton appointed, Carl Gordon stepping down; Esther Cho promoted to Chief Legal Officer

Financial Impact

Revenue increased from $3.55M in 2024 to $244.06M in 2025, driven by $205.36M in license revenue. Net loss turned into net income of $87.0M. Cash decreased by $272.5M year-over-year.

revenuenet_incomecashr_and_d_expense

Risk Factors

  • Revenue surge is largely one-time license income; future revenue depends on clinical progress and partnerships
  • Cash burn remains high on operating basis; future funding may require dilution or new partnerships
  • Clinical development risk for rinvatercept in DMD and ALS is high given early-stage nature
  • Loss of key personnel or delays in trial initiation could impact timeline and valuation

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3249712

Track record

27 reports on KROS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
  3. Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  5. Nov 5, 202611d ago Press Release Neutral 5/10 No price data
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
  7. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
  8. Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  9. Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  10. Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 4, 2026